Status:
TERMINATED
Mesenchymal Stromal Cells as Treatment of Chronic Graft-versus-host Disease
Lead Sponsor:
Karolinska Institutet
Collaborating Sponsors:
Region Stockholm
Conditions:
Graft-Versus-Host Disease
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The aim of the study is to evaluate the safety and efficacy of mesenchymal stromal cells as treatment for steroid-refractory chronic graft-versus-host disease.
Eligibility Criteria
Inclusion
- Chronic graft-versus-host disease, grade moderate or severe despite at least 3 months treatment with calcineurin inhibitors and steroids OR
- Chronic graft-versus-host disease, grade moderate or severe, where full treatment with calcineurin inhibitors and steroids is impossible due to intolerable side-effects
Exclusion
- Active malignancy
- Fulfilling criteria for previously initiated study for treatment of chronic graft-versus-host disease
Key Trial Info
Start Date :
August 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2017
Estimated Enrollment :
11 Patients enrolled
Trial Details
Trial ID
NCT01522716
Start Date
August 1 2011
End Date
March 1 2017
Last Update
November 25 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hematology Center, Karolinska University Hospital Huddinge
Stockholm, Sweden